Cornell University
Recombinant Escherichia coli derived outer membrane vesicles for safe and effective subunit antigen delivery
Abstract
dc:description.abstractSubunit vaccines rely on adjuvants to drive an immune response against antigens of interest. Improved adjuvant platforms, capable of interaction with specific pathogen recognition receptors in the innate immune system, can lead to more effective and longer lasting vaccines. Recombinant outer membrane vesicles (rOMVs) are a recently developed adjuvant system that harnesses the natural pathogen associated molecular patterns present in the outer membrane of E. coli to direct an immune response against recombinant antigens displayed on the rOMV surface. Though rOMV vaccines have demonstrated promise against viral antigens in murine models, their high lipopolysaccharide (LPS) content hinders translation to humans. This dissertation will present ways in which the LPS in rOMVs can be modified, through use of ‘detoxified’ commercial E. coli strains, as well as through genetic manipulation of probiotic E. coli strains, to generate rOMVs with greatly improved safety profiles. Additionally, it will profile the development of a potential pandemic influenza vaccine using detoxified rOMVs, demonstrating their feasibility in achieving protective immune responses.
Degree
thesis:*- Name thesis:degree_name
- Ph. D., Biomedical Engineering
- Level thesis:degree_level
- Doctor of Philosophy
- Discipline thesis:degree_discipline
- Biomedical Engineering
- Grantor
- Cornell University
- Year dc:date.issued
- 2017
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Watkins, Hannah Christine
- Chair dc:contributor.chair
-
- Putnam, David A.
- Committee members dc:contributor.committeemember
-
- Delisa, Matthew
- Whittaker, Gary R
Subjects
dc:subject × 9Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Dc Identifier Bibid
- 9906090
- Dc Identifier Other
-
ProQuest Submission ID: 10101
ProQuest Publication ID: 10252363